https://losmapimodinhibitor.co....m/uveal-cancer-metas
We retrospectively reviewed the standard information, including clinicopathologic attributes, laboratory variables, and peripheral protected features reflecting T-cell function, from three HCC cohorts. A gradient-boosting survival (GBS) classifier was trained with prognosis-related variables within the instruction dataset and validated in two independent cohorts. We built a 20-feature GBS design classifier incorporating one medical feature, 14 laboratory parameter
Like
Comment
Share
